How Carcinogens Cause Cancer: The Mechanism of Carcinogenesis

Cancer doesn’t happen overnight. It’s the result of a long, step-by-step process where normal cells accumulate damage and gradually transform into malignant ones. This process – called carcinogenesis – involves specific stages, key genetic players, and the failure of the body’s built-in repair systems. Understanding how carcinogens cause cancer at the molecular level is essential for anyone studying environmental health, toxicology, or public health. Let’s break down the mechanism of carcinogenesis in a clear, structured way.

The multistage model of carcinogenesis
Initiation: the first hit
Promotion: fueling the fire
Progression: the point of no return
Roles of oncogenes and tumor suppressor genes
Oncogenes: the stuck accelerator
Tumor suppressor genes: the broken brakes
DNA damage and the role of repair mechanisms
How carcinogens damage DNA
The body’s DNA repair toolkit
When repair fails: the path to cancer
Putting it all together

The multistage model of carcinogenesis

Cancer development is not a single event. It is a multistage process that unfolds over years or even decades, involving distinct phases: initiation, promotion, and progression. Each stage has its own biological characteristics and involves different types of cellular changes. Scientists first recognized this stepwise nature through experiments on mouse skin using chemical carcinogens and promoters, and the model has since been validated across many tissue types in both animals and humans.

Initiation: the first hit

Initiation is the first and most critical step. It occurs when a carcinogenic agent – whether a chemical, radiation, or virus – causes permanent, irreversible damage to a cell’s DNA. This damage typically involves the formation of DNA adducts, which are chemical groups that attach to the DNA molecule and alter its structure. During DNA replication, these adducts can lead to point mutations if not correctly repaired.

The key feature of initiation is that the genetic change is irreversible. Once a cell’s DNA has been mutated in a way that affects growth-controlling genes, that cell is considered “initiated.” However, initiation alone is not enough to cause cancer. A single initiated cell, left on its own without further stimulus, may never become a tumor. There is generally a strong correlation between the amount of carcinogen-DNA adducts formed in a tissue and the likelihood of tumors developing there.

Promotion: fueling the fire

After initiation, the second stage is promotion. Tumor promoters are agents that are not themselves mutagenic – they don’t directly damage DNA. Instead, they stimulate the initiated cells to divide and multiply, creating a growing population of abnormal cells. This stage is characterized by clonal expansion, where a group of initiated cells proliferates selectively.

Unlike initiation, promotion is considered potentially reversible in its early phases. If the promoting stimulus is removed early enough, the precancerous changes may not advance further. Common examples of tumor promoters include alcohol, chronic inflammation, certain hormones like estrogen, dietary fat, ultraviolet light, and industrial chemicals such as dioxin and polychlorinated biphenyls (PCBs). These agents work by reducing the time between initiation and visible tumor formation or by increasing the number of tumors in the affected tissue.

An important point: promotion requires repeated and sustained exposure to the promoting agent. A single brief exposure to a promoter typically will not result in tumor development. This is why chronic environmental or occupational exposures are particularly concerning from a public health perspective.

Progression: the point of no return

The final stage, progression, is where precancerous cells acquire enough additional genetic changes to become fully malignant. During progression, cells develop the hallmark characteristics of cancer: genomic instability, rapid and uncontrolled growth, the ability to invade surrounding tissues, and the capacity to metastasize to distant organs.

Progression involves further mutations that can be accelerated by continued exposure to DNA-damaging agents. These mutations frequently target proto-oncogenes and tumor suppressor genes – the two major categories of cancer-related genes. The conversion from a benign, preneoplastic lesion into a fully invasive cancer represents a qualitative shift in cell behavior, making progression the most dangerous and clinically significant stage.

Roles of oncogenes and tumor suppressor genes

At the genetic level, cancer is driven by two main types of gene alterations: the activation of oncogenes and the inactivation of tumor suppressor genes. Both play opposing roles in cell growth regulation, and cancer typically requires disruptions in both systems.

Oncogenes: the stuck accelerator

Every normal cell contains genes called proto-oncogenes that help regulate cell growth, division, and survival. These genes are essential for normal development and tissue maintenance. However, when a proto-oncogene is altered by a mutation, gene amplification, or chromosomal rearrangement, it can become an oncogene – a gene that drives uncontrolled cell proliferation.

One of the most well-known oncogenes is RAS. The RAS family of genes encodes small signaling proteins that relay growth signals inside the cell. When a RAS gene is mutated, it becomes permanently active, continuously sending signals for the cell to divide regardless of whether external growth signals are present. According to the American Cancer Society, mutations in the RAS gene are found in approximately 20% of all human cancers. The RAS proteins are membrane-bound, possess GTPase activity, and exert a strong proliferative effect through signal transduction cascades.

Oncogenes can be activated in several ways: a single point mutation in the gene’s coding sequence, an increase in the number of copies of the gene (amplification), or a chromosomal translocation that places the gene under the control of a highly active promoter. In each case, the result is excessive or inappropriate cell growth signaling.

Tumor suppressor genes: the broken brakes

While oncogenes act as accelerators, tumor suppressor genes function as the cell’s braking system. These genes normally slow down cell division, trigger programmed cell death (apoptosis) when cells are damaged, or activate DNA repair. When tumor suppressor genes are inactivated through mutation, deletion, or epigenetic silencing, cells lose critical growth controls.

The most studied tumor suppressor gene is TP53, which encodes the protein p53, often referred to as the “guardian of the genome.” When a cell’s DNA is damaged, p53 activates pathways that halt the cell cycle, giving the cell time to repair the damage. If the damage is too severe, p53 triggers apoptosis, eliminating the potentially dangerous cell. The TP53 gene is mutated in over 50% of human cancers, making it the most commonly altered gene in cancer biology. When p53 is non-functional, damaged cells continue dividing and accumulating additional mutations, accelerating the path toward malignancy.

Another important example is the retinoblastoma gene (RB1), which controls cell cycle progression. Loss of both functional copies of RB1 leads to retinoblastoma, a childhood eye cancer. This discovery led to the well-known Knudson two-hit hypothesis, which states that both alleles of a tumor suppressor gene must be inactivated for cancer to develop – one through inheritance or early mutation, and the second through a later somatic event.

What makes the oncogene-tumor suppressor interplay especially dangerous is that they often cooperate. For example, research has shown that simultaneous RAS activation and p53 inactivation leads to expression of genes that promote invasion, angiogenesis, and metastasis – effects that neither alteration produces alone.

DNA damage and the role of repair mechanisms

DNA damage is the initiating event in carcinogenesis, but whether that damage leads to cancer depends largely on the cell’s ability to repair it. The human body has evolved a sophisticated network of DNA repair systems that detect and fix various types of damage before it becomes permanent. When these systems fail, mutations accumulate, and the risk of cancer increases significantly.

How carcinogens damage DNA

Carcinogens damage DNA through multiple mechanisms. Chemical carcinogens such as polycyclic aromatic hydrocarbons (found in tobacco smoke and grilled meat) and aflatoxins (produced by certain molds) are often procarcinogens – they are chemically inactive in their original form and must be metabolized by the body’s enzymes into reactive intermediates. These reactive metabolites then form covalent bonds with nucleotides in DNA, creating bulky DNA adducts that distort the double helix.

Physical carcinogens like ultraviolet (UV) radiation cause pyrimidine dimers – abnormal bonds between adjacent bases on the same DNA strand. Ionizing radiation (such as X-rays) generates reactive oxygen species (ROS) that can cause both single-strand and double-strand breaks in the DNA. Double-strand breaks are considered the most harmful form of DNA damage because they can lead to chromosomal rearrangements if repaired incorrectly.

The body’s DNA repair toolkit

Cells have multiple repair pathways, each designed to handle specific types of damage. The major systems include:

Base excision repair (BER) fixes small, non-bulky lesions such as oxidized or alkylated bases. Enzymes called glycosylases recognize and remove the damaged base, and the gap is filled using the undamaged complementary strand as a template.

Nucleotide excision repair (NER) handles bulky, helix-distorting lesions like those caused by UV radiation or chemical adducts. NER cuts out a short stretch of the damaged strand and replaces it with the correct sequence. Defects in NER genes cause xeroderma pigmentosum, a rare condition that dramatically increases sensitivity to sunlight and skin cancer risk.

Mismatch repair (MMR) corrects errors that slip past the DNA polymerase’s proofreading function during replication, particularly insertions, deletions, and base misincorporations. Defects in MMR genes are associated with hereditary colorectal cancer (Lynch syndrome) and significantly elevated mutation rates.

Homologous recombination (HR) and non-homologous end joining (NHEJ) are the two main pathways for repairing double-strand breaks. HR uses the sister chromatid as a template and is generally accurate, while NHEJ directly joins broken ends and can introduce errors. Mutations in the HR-related genes BRCA1 and BRCA2 are found in a significant percentage of hereditary breast and ovarian cancers, as noted by the National Cancer Institute.

When repair fails: the path to cancer

When DNA damage overwhelms the repair capacity of a cell, or when the repair machinery itself is defective, mutations become permanent and are passed to daughter cells during division. If these mutations occur in oncogenes or tumor suppressor genes, the cell moves closer to malignant transformation. The accumulation of such errors over a lifetime is a key reason why cancer incidence rises with age.

The relationship between DNA damage, repair, and carcinogenesis is essentially a balance. On one side, DNA-damaging agents constantly challenge genomic integrity. On the other, repair mechanisms work to maintain stability. Cancer develops when this balance tips – either through excessive damage, inadequate repair, or both.

It’s also worth noting that epigenetic changes can silence DNA repair genes without altering their sequence. Promoter methylation of repair genes, for example, can shut down their expression, leading to a “mutator phenotype” where the cell accumulates mutations at an accelerated rate. This epigenetic silencing of repair genes has been observed across many cancer types and represents another important pathway to genomic instability.

Putting it all together

The mechanism of carcinogenesis is best understood as an interplay between external insults and internal defenses. A carcinogen damages DNA, creating the potential for harmful mutations. If the cell’s repair systems catch and fix the damage, no lasting harm is done. But if the damage escapes repair – or if repair genes themselves are compromised – mutations can persist. Over time, the right combination of oncogene activation and tumor suppressor inactivation pushes cells through initiation, promotion, and progression, ultimately leading to cancer.

This understanding has practical implications. It explains why reducing exposure to known carcinogens (like tobacco smoke, UV radiation, and certain industrial chemicals) lowers cancer risk – fewer DNA-damaging events mean fewer chances for mutations to take hold. It also explains why individuals with inherited defects in DNA repair genes, such as those carrying BRCA mutations or those with xeroderma pigmentosum, face elevated cancer risks even without unusual environmental exposures.

What do you think? Given that our bodies are constantly exposed to DNA-damaging agents yet most cells never become cancerous, how effective do you think our DNA repair systems really are – and what role should environmental policy play in reducing the carcinogenic burden we all face?

References

PDF 📄

Table of Contents

The multistage model of carcinogenesis 🔗

Initiation: the first hit 🔗

Promotion: fueling the fire 🔗

Progression: the point of no return 🔗

Roles of oncogenes and tumor suppressor genes 🔗

Oncogenes: the stuck accelerator 🔗

Tumor suppressor genes: the broken brakes 🔗

DNA damage and the role of repair mechanisms 🔗

How carcinogens damage DNA 🔗

The body’s DNA repair toolkit 🔗

When repair fails: the path to cancer 🔗

Putting it all together 🔗